
EquityIndex FundsVery High Risk
Regular
NAV (13-Feb-26)
Returns (Since Inception)
Fund Size
₹167 Cr
Expense Ratio
1.06%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.10%
— (Cat Avg.)
3 Years
+20.37%
— (Cat Avg.)
5 Years
+13.45%
— (Cat Avg.)
Since Inception
+14.90%
— (Cat Avg.)
| Equity | ₹166.53 Cr | 99.81% |
| Others | ₹0.32 Cr | 0.19% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹18.19 Cr | 10.90% |
| Eli Lilly and Co | Equity | ₹10.47 Cr | 6.27% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.92 Cr | 5.35% |
| Cipla Ltd | Equity | ₹8.9 Cr | 5.33% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.84 Cr | 5.30% |
| Divi's Laboratories Ltd | Equity | ₹8.59 Cr | 5.15% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.85 Cr | 4.71% |
| Johnson & Johnson | Equity | ₹6.87 Cr | 4.12% |
| Lupin Ltd | Equity | ₹6.43 Cr | 3.85% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.58 Cr | 3.34% |
| Fortis Healthcare Ltd | Equity | ₹4.97 Cr | 2.98% |
| AbbVie Inc | Equity | ₹4.94 Cr | 2.96% |
| Laurus Labs Ltd | Equity | ₹4.02 Cr | 2.41% |
| Aurobindo Pharma Ltd | Equity | ₹3.75 Cr | 2.25% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹3.72 Cr | 2.23% |
| Novartis AG ADR | Equity | ₹3.55 Cr | 2.13% |
| Merck & Co Inc | Equity | ₹3.46 Cr | 2.07% |
| Alkem Laboratories Ltd | Equity | ₹3.23 Cr | 1.93% |
| Mankind Pharma Ltd | Equity | ₹3.13 Cr | 1.87% |
| Thermo Fisher Scientific Inc | Equity | ₹2.74 Cr | 1.64% |
| Ipca Laboratories Ltd | Equity | ₹2.44 Cr | 1.46% |
| Novo Nordisk AS ADR | Equity | ₹2.4 Cr | 1.44% |
| Abbott Laboratories | Equity | ₹2.39 Cr | 1.43% |
| Biocon Ltd | Equity | ₹2.33 Cr | 1.40% |
| Amgen Inc | Equity | ₹2.31 Cr | 1.38% |
| Intuitive Surgical Inc | Equity | ₹2.27 Cr | 1.36% |
| Gilead Sciences Inc | Equity | ₹2.21 Cr | 1.32% |
| Zydus Lifesciences Ltd | Equity | ₹2.12 Cr | 1.27% |
| Danaher Corp | Equity | ₹1.77 Cr | 1.06% |
| Medtronic PLC | Equity | ₹1.66 Cr | 0.99% |
| Gland Pharma Ltd | Equity | ₹1.63 Cr | 0.98% |
| Stryker Corp | Equity | ₹1.6 Cr | 0.96% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹1.53 Cr | 0.92% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.52 Cr | 0.91% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.5 Cr | 0.90% |
| Ajanta Pharma Ltd | Equity | ₹1.45 Cr | 0.87% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.21 Cr | 0.72% |
| Piramal Pharma Ltd | Equity | ₹1.1 Cr | 0.66% |
| Syngene International Ltd | Equity | ₹1.02 Cr | 0.61% |
| Global Health Ltd | Equity | ₹1.01 Cr | 0.61% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.97 Cr | 0.58% |
| Becton Dickinson & Co | Equity | ₹0.73 Cr | 0.44% |
| IQVIA Holdings Inc | Equity | ₹0.49 Cr | 0.30% |
| Agilent Technologies Inc | Equity | ₹0.48 Cr | 0.29% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.45 Cr | 0.27% |
| Illumina Inc | Equity | ₹0.28 Cr | 0.17% |
| Net Receivables/(Payables) | Cash - Collateral | ₹-0.13 Cr | 0.08% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
40.08%
Mid Cap Stocks
23.88%
Small Cap Stocks
4.03%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹166.53 Cr | 99.81% |
Standard Deviation
This fund
12.34%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.96
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021

Since February 2021
ISIN INF754K01LR3 | Expense Ratio 1.06% | Exit Load No Charges | Fund Size ₹167 Cr | Age 5 years 3 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,05,318 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments